Medication info
Daparon Duo Extended-Release Tablets 10/1000 mg

Daparon Duo Extended-Release Tablets 10/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletDapagliflozin Bis L-proline›15.6mg / 1 tablet
Manufacturer / importer
Hanmih Pharmaceutical Co., Ltd.
Appearance
Yellow, bilaterally convex, oval-shaped extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202202500 · Approved 2022.06.15 · Insurance code 643508590

Summary

Main use
Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior history of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug treatment, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients treated with metformin, the recommended dose of dapagliflozin is 10mg once daily; the dose of this medicine should provide the same dose of metformin the patient was taking, or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. For patients switching to this medicine from combination therapy with dapagliflozin and metformin, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other antihyperglycemic agents. Because any change may cause changes in glycemic control, changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. Swallow this medicine whole. Do not crush, cut, or chew it. Occasionally, the inactive ingredients of this medicine may be excreted in the feces as a soft hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, and without other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, an ingredient of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, discontinue this medicine immediately. Renal function should be assessed every 3~6 months. Elderly patients Since metformin is excreted through the kidneys and renal function is more likely to be reduced in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Ingredients

Manufacturer
Hanmih Pharmaceutical Co., Ltd.

Efficacy & effects

Improves glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • impaired blood sugar control
  • cardiovascular diseases
  • cardiovascular risk factors
View approved original text

This medication is used together with dietary and exercise therapies to assist in blood sugar control for patients with type 2 diabetes. Taking dapagliflozin and metformin together can effectively improve blood sugar levels. Particularly for patients with cardiovascular diseases or risk factors, careful management according to the physician's instructions is required when taking this medication. This medication helps to maintain a healthy state by regulating blood sugar levels along with appropriate lifestyle habits.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior history of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug treatment, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients treated with metformin, the recommended dose of dapagliflozin is 10mg once daily; the dose of this medicine should provide the same dose of metformin the patient was taking, or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. For patients switching to this medicine from combination therapy with dapagliflozin and metformin, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other antihyperglycemic agents. Because any change may cause changes in glycemic control, changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. Swallow this medicine whole. Do not crush, cut, or chew it. Occasionally, the inactive ingredients of this medicine may be excreted in the feces as a soft hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, and without other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, an ingredient of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, discontinue this medicine immediately. Renal function should be assessed every 3~6 months. Elderly patients Since metformin is excreted through the kidneys and renal function is more likely to be reduced in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Precautions

This medication is used for the treatment of diabetes and helps manage blood sugar levels. However, it should not be used in patients with impaired kidney function, acute infections, or severe heart diseases. Additionally, it is safer not to administer it to pregnant or breastfeeding women. This medication can rarely cause a serious condition called lactic acidosis, so if symptoms such as muscle pain, difficulty breathing, or weakness occur, consult a doctor immediately. When used in combination with insulin or other diabetes medications, there is a risk of hypoglycemia, so caution is necessary. Patients with reduced fluid volume or low blood pressure, especially the elderly or those using diuretics, must ensure kidney function and fluid status are confirmed before starting this medication. Regular monitoring for symptoms of low blood pressure or changes in kidney function is needed during use. This medication may increase the risk of genital and urinary infections, requiring prompt treatment if infection symptoms occur. Also, vitamin B12 deficiency may develop, so it is advisable to check vitamin B12 levels during long-term use. Excessive alcohol should be avoided, and it is recommended to discontinue the medication for a certain period before surgery or X-ray examinations. Weight loss and increased urine output may occur during the use of this medication, so these should be monitored. In case of overdose, seek immediate medical attention.

Side effects

  • severe lactic acidosis
  • hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • decreased fluid volume
  • thirst
  • diabetic ketoacidosis
Show 83 more
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • increased serum creatinine
  • increased blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • lung malignancy
  • uterine fibroid
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • paresthesia
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • herpes zoster
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood glucose
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • swelling
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • pruritus
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is best to keep the storage temperature between 1 degree and 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

Yellow, bilaterally convex, oval-shaped extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.